63 Rec'e CT/PTO 08 DEC 1998 09/101413

ON 1998 PN THE UN

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hans Josef Stauss

Serial No.:

09/101,413

Art Unit:

Filed:

July 10, 1998

Examiner:

For:

Immunotherapy Using Cytotoxic T Lymphocytes (CTL)

Assistant Commissioner for Patents

Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form 1449 and a copy of the document cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first office action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Assistant Commissioner is authorized to charge any fees to Deposit Account No. 01-2507.

Publications

Yang, et al. "Major Histocompatability Complex (MHC)-encoded HAM2 Is Necessary for Antigenic Peptide Loading onto Class I MHC Molecules" *J. Biol. Chem.* 267: 11669-11672 (1992).

U.S.S.N.:

09/101,413

Filed:

July 10, 1998

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Dated: December 4, 1998

ARNALL GOLDEN & GREGORY 2800 One Atlantic Center 1201 W. Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax)

U.S.S.N.: 09/101,413
Filed July 10, 1998

ENTRY INFORMATION DISCLOSURE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

December 4, 1998

Kristin Herring